carcinogenicity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
=== Supply chain and operational impacts === The pandemic initially disrupted blood donation and collection services due to lockdowns and social distancing requirements. However, it also spurred innovation in contactless and at-home collection methods, with companies developing low-volume sample collection technologies that require as little as 1 mL of blood compared to traditional testing requiring 50-130 mL.
Pindolol, sold under the brand name Visken among others, is a non-selective beta blocker which is used in the treatment of hypertension. It is also an antagonist of the serotonin 5-HT1A receptor, preferentially blocking inhibitory 5-HT1A autoreceptors, and has been researched as an add-on therapy to various antidepressants, such as clomipramine and the selective serotonin reuptake inhibitors (SSRIs), in the treatment of depression and obsessive–compulsive disorder (OCD).
The ultimate clinical candidate, D2E7, was created and manufactured at BASF Bioresearch Corporation and taken through most of the drug development process by BASF Knoll, then further development, manufacturing and marketing by Abbott Laboratories, after Abbott acquired the pharmaceutical arm of BASF Knoll. Since 2008, adalimumab had been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012, by the FDA in the disease's management, it had been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's disease. Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002. Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.
In April 2025, Hegseth issued a directive to the secretary of the Army ordering on a sweeping overhaul, prioritizing defending the homeland and deterring China in the Indo-Pacific. Among others, the directive instructing a consolidated budget lines in unmanned systems, counter-drone systems and electronic warfare, force structure changes and expanded use of other transaction agreements. The directive also instructed to downsize or close redundant headquarters as well as merging Army Futures Command and Training and Doctrine Command, and merging four-star headquarters Army Forces Command with Army North and Army South into a single headquarters focused on homeland defense as well as the elimination of at least 20% of four-star general positions to enhance efficiency and operational effectiveness. Hegseth also signed a memorandum to reduce the Department of Defense's civilian workforce, aiming to eliminate duplicative efforts and excessive bureaucracy. The initiative includes offering voluntary early retirement and deferred resignation programs to incentivize top performers and enhance efficiency. That month, Hegseth received criticism from some Senate Democrats over alleged civilian deaths in the Yemen strikes.
Sources: en.wikipedia.org
=== Scraped surface generators === The world’s first patent for a slurry ice generator was filed by Sunwell Technologies Inc. of Canada in 1976. Sunwell Technologies Inc. introduced slurry ice under the trade name deepchill ice, in the late 1970s. Slurry ice is created through a process of forming spherical ice crystals within a liquid. The slurry ice generator is a scraped-surface vertical shell and tube heat exchanger. It consists of concentric tubes with refrigerant flowing between them and the water/freezing point depressant solution in the inner tube. The inner surface of the inner tube is wiped using a mechanism which in the original Sunwell design consists of a central shaft, spring-loaded plastic blades, bearings, and seals. The small ice crystals formed in the solution near the tube surface are wiped away from the surface and mixed with unfrozen water, forming the slurry. Other slurry ice generators adapted the first idea of wiping the surface using an auger originally designed to create flake ice. Wipers also can be brushes or fluidized bed heat exchangers for ice crystallization. In these heat exchangers, steel particles circulate with the fluid, mechanically removing the crystals from the surface. At the outlet, steel particles and slurry ice are separated.
He further added, "Nobody's done anything great over there. The whole place is a mess... I told Israel maybe they have to do it a different way." Israeli Prime Minister said, "And what has interdicted the supply of humanitarian aid is one force, Hamas. Again, the reversal of truth." Asked about an Israeli double-strike on a hospital on August 25, 2025, Trump said he was "not happy about it", adding, "We have to end this whole nightmare."
The National Institutes of Health Clinical Center, the world's largest clinical research hospital, is designed to foster smooth transitions between laboratory work, patient studies, and bedside cures, facilitating the translation of laboratory findings to new approaches for the prevention and cure of human diseases.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.